Pro-Dex Inc (NASDAQ:PDEX) was the recipient of a large decrease in short interest in July. As of July 15th, there was short interest totalling 12,600 shares, a decrease of 36.7% from the June 15th total of 19,900 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average trading volume of 25,900 shares, the short-interest ratio is presently 0.5 days.

PDEX stock traded up $0.38 on Friday, reaching $14.42. 10,754 shares of the company traded hands, compared to its average volume of 8,901. Pro-Dex has a one year low of $6.15 and a one year high of $17.95. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.60 and a current ratio of 5.88. The company has a market cap of $57.74 million, a P/E ratio of 17.77 and a beta of 1.42. The firm’s fifty day simple moving average is $12.93.

Pro-Dex (NASDAQ:PDEX) last posted its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.17 earnings per share for the quarter. Pro-Dex had a return on equity of 19.69% and a net margin of 12.98%. The company had revenue of $6.85 million during the quarter.

A number of research analysts recently weighed in on the company. Ascendiant Capital Markets set a $2,000.00 price objective on Booking and gave the company a “buy” rating in a research report on Tuesday, May 14th. ValuEngine raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday.

In related news, Director Raymond E. Cabillot sold 8,977 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $17.66, for a total transaction of $158,533.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kirk Richard Lee Van, Jr. acquired 3,500 shares of Pro-Dex stock in a transaction that occurred on Tuesday, May 14th. The shares were bought at an average cost of $13.25 per share, with a total value of $46,375.00. Following the transaction, the chief executive officer now owns 24,897 shares in the company, valued at $329,885.25. The disclosure for this purchase can be found here. 41.70% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. O Shaughnessy Asset Management LLC bought a new position in Pro-Dex during the 1st quarter valued at approximately $242,000. Acadian Asset Management LLC boosted its stake in Pro-Dex by 82.2% during the 1st quarter. Acadian Asset Management LLC now owns 75,253 shares of the medical instruments supplier’s stock valued at $1,089,000 after purchasing an additional 33,940 shares during the last quarter. Alambic Investment Management L.P. boosted its stake in Pro-Dex by 6.2% during the 1st quarter. Alambic Investment Management L.P. now owns 73,583 shares of the medical instruments supplier’s stock valued at $1,065,000 after purchasing an additional 4,291 shares during the last quarter. BlackRock Inc. boosted its stake in Pro-Dex by 49.2% during the 4th quarter. BlackRock Inc. now owns 12,369 shares of the medical instruments supplier’s stock valued at $150,000 after purchasing an additional 4,078 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Pro-Dex during the 4th quarter valued at $183,000. 12.96% of the stock is owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc, together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection molds for various industries; and shavers and machined parts. In addition, it provides engineering, and quality and regulatory consulting services.

See Also: The mechanics of the bid-ask spread in trading

Receive News & Ratings for Pro-Dex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pro-Dex and related companies with MarketBeat.com's FREE daily email newsletter.